Brain scans track tau changes after Alzheimer's antibody treatment

NCT ID NCT06723015

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses special brain scans (tau PET) to see how anti-amyloid immunotherapy affects tau protein buildup in people with mild Alzheimer's disease. About 135 participants will get two tau PET scans—one before starting treatment and another 12-18 months after finishing it. The goal is to learn whether clearing amyloid plaques also slows tau spread, which could improve future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-AV-1451 (a radioactive tracer for tau PET scans)
What this could lead to: If successful, this could help doctors understand whether anti-amyloid therapies slow tau spread in the brain, guiding future Alzheimer's treatment.
What could go wrong: This is an observational imaging study, not a treatment trial. It may not show clear changes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE COGNITIVE IMPAIRMENT, MILD DEMENTIA, MILD

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.